Literature DB >> 10024514

Synergistic activation of JNK/SAPK by interleukin-1 and platelet-derived growth factor is independent of Rac and Cdc42.

W Davis1, L R Stephens, P T Hawkins, J Saklatvala.   

Abstract

The c-Jun N-terminal kinases (JNKs) are activated strongly by inflammatory cytokines and environmental stresses, but only weakly by growth factors. Here we show that platelet-derived growth factor (PDGF) strongly potentiates activation of JNK by interleukin 1 (IL-1) in human fibroblasts and a pig aortic endothelial (PAE) cell line. This synergistic activation of JNK by IL-1 and PDGF was unaffected by bacterial toxins that inactivate Rho proteins and Ras. Since Rho proteins have been implicated in JNK activation, their possible involvement was investigated further using stably expressed, inducible N17 or V12 mutants in PAE cell lines. N17 Rac non-selectively reduced JNK activity by 30% in resting or stimulated cells (IL-1 alone, or with PDGF). N17 Cdc42 had no effect. V12 Rac weakly activated JNK and synergized with IL-1, but not with PDGF. V12 Cdc42 weakly activated JNK, but synergized with PDGF and not IL-1. Our results imply that Rho GTPases are not directly involved in mediating IL-1-induced JNK activation, or in the potentiation of this activation by PDGF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024514      PMCID: PMC1220064     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF.

Authors:  T G Boulton; S H Nye; D J Robbins; N Y Ip; E Radziejewska; S D Morgenbesser; R A DePinho; N Panayotatos; M H Cobb; G D Yancopoulos
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

2.  B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase.

Authors:  B Westermark; A Siegbahn; C H Heldin; L Claesson-Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

3.  Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase.

Authors:  A J Rossomando; D M Payne; M J Weber; T W Sturgill
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Activation of phosphoinositide 3-kinase is required for PDGF-stimulated membrane ruffling.

Authors:  S Wennström; P Hawkins; F Cooke; K Hara; K Yonezawa; M Kasuga; T Jackson; L Claesson-Welsh; L Stephens
Journal:  Curr Biol       Date:  1994-05-01       Impact factor: 10.834

5.  JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.

Authors:  B Dérijard; M Hibi; I H Wu; T Barrett; B Su; T Deng; M Karin; R J Davis
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

6.  The stress-activated protein kinase subfamily of c-Jun kinases.

Authors:  J M Kyriakis; P Banerjee; E Nikolakaki; T Dai; E A Rubie; M F Ahmad; J Avruch; J R Woodgett
Journal:  Nature       Date:  1994-05-12       Impact factor: 49.962

7.  Interleukin-1 activates a novel protein kinase that phosphorylates the epidermal-growth-factor receptor peptide T669.

Authors:  M Kracht; M Shiroo; C J Marshall; J J Hsuan; J Saklatvala
Journal:  Biochem J       Date:  1994-09-15       Impact factor: 3.857

8.  The binding subunit of pertussis toxin inhibits IL-1 induction of IL-2 and prostaglandin production.

Authors:  L A O'Neill; T Ikebe; S J Sarsfield; J Saklatvala
Journal:  J Immunol       Date:  1992-01-15       Impact factor: 5.422

9.  Effect of tumor necrosis factor on GTP binding and GTPase activity in HL-60 and L929 cells.

Authors:  K Imamura; M L Sherman; D Spriggs; D Kufe
Journal:  J Biol Chem       Date:  1988-07-25       Impact factor: 5.157

10.  Interleukin 1 alpha activates two forms of p54 alpha mitogen-activated protein kinase in rabbit liver.

Authors:  M Kracht; O Truong; N F Totty; M Shiroo; J Saklatvala
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  6 in total

1.  Analysis of mitogen-activated protein kinase pathways used by interleukin 1 in tissues in vivo: activation of hepatic c-Jun N-terminal kinases 1 and 2, and mitogen-activated protein kinase kinases 4 and 7.

Authors:  A Finch; W Davis; W G Carter; J Saklatvala
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

2.  Actin can reorganize into podosomes in aortic endothelial cells, a process controlled by Cdc42 and RhoA.

Authors:  Violaine Moreau; Florence Tatin; Christine Varon; Elisabeth Génot
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

3.  Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38.

Authors:  M Lasa; M Brook; J Saklatvala; A R Clark
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 4.  The Immune Response in Adipocytes and Their Susceptibility to Infection: A Possible Relationship with Infectobesity.

Authors:  Orestes López-Ortega; Nidia Carolina Moreno-Corona; Victor Javier Cruz-Holguin; Luis Didier Garcia-Gonzalez; Addy Cecilia Helguera-Repetto; Mirza Romero-Valdovinos; Haruki Arevalo-Romero; Leticia Cedillo-Barron; Moisés León-Juárez
Journal:  Int J Mol Sci       Date:  2022-05-31       Impact factor: 6.208

5.  Regulation of endothelial cell cytoskeletal reorganization by a secreted frizzled-related protein-1 and frizzled 4- and frizzled 7-dependent pathway: role in neovessel formation.

Authors:  Pascale Dufourcq; Lionel Leroux; Jérome Ezan; Betty Descamps; Jean-Marie Daniel Lamazière; Pierre Costet; Caroline Basoni; Catherine Moreau; Urban Deutsch; Thierry Couffinhal; Cécile Duplàa
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

6.  MMP-9 and CXCL8/IL-8 are potential therapeutic targets in epidermolysis bullosa simplex.

Authors:  Thomas Lettner; Roland Lang; Alfred Klausegger; Stefan Hainzl; Johann W Bauer; Verena Wally
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.